@article {7554,
	title = {Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma},
	journal = {Blood Cancer Journal},
	volume = {4},
	year = {2014},
	note = {Cited By :25Export Date: 21 February 2017},
	month = {2014},
	abstract = {The addition of vorinostat to lenalidomide/dexamethasone represents a novel combination therapy in multiple myeloma (MM), informed by laboratory studies suggesting synergy. This was a phase I, multicenter, open-label, non-randomized, dose-escalating study in patients with relapsed or relapsed and refractory MM. Clinical evaluation, electrocardiogram, laboratory studies and adverse events were obtained and assessed. The maximum-tolerated dose was not reached owing to a non-occurrence of two dose-limiting toxicities per six patients tested at any of the dosing levels. Patients tolerated the highest dose tested (Level 5) and this was considered the maximum administered dose: at 400mg vorinostat on days 1-7 and 15-21, 25mg lenalidomide on days 1-21 and 40mg dexamethasone on days 1, 8, 15 and 22, per 28-day cycle. Drug-related adverse events were reported in 90\% of patients serious adverse experiences were reported in 45\% of the patients and 22\% of all patients had adverse experiences considered, possibly related to study drug by the investigators. A confirmed partial response or better was reported for 14/30 patients (47\%) evaluable for efficacy, including 31\% of patients previously treated with lenalidomide. Vorinostat in combination with lenalidomide and dexamethasone proved tolerable with appropriate supportive care, with encouraging activity observed. {\textcopyright} 2014 Macmillan Publishers Limited.},
	keywords = {Lenalidomide, multiple myeloma, refractory, relapsed, Vorinostat},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895419209\&doi=10.1038\%2fbcj.2014.1\&partnerID=40\&md5=dc1dce0ba410fa1ce297213dbc27b787},
	author = {Siegel, D.S. and Richardson, P. and Dimopoulos, M. and Moreau, P. and Mitsiades, C. and Weber, D. and Houp, J. and Gause, C. and Vuocolo, S. and Eid, J. and Graef, T. and Anderson, K.C.}
}
